Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Thymosin Alpha-1 + Thymalin Protocol
TA1/Thymalin Stack, Immune Peptide Protocol
LL-37
Cathelicidin, Human Cathelicidin Antimicrobial Peptide
A combination protocol pairing Thymosin Alpha-1 (a 28-amino acid thymic peptide) with Thymalin (a thymic extract) for comprehensive immune system modulation. Based on the work of Vladimir Khavinson, this stack targets both innate and adaptive immunity. Used in integrative medicine for immune optimization, post-illness recovery, and longevity protocols.
The only human cathelicidin antimicrobial peptide, LL-37 is a 37-amino-acid peptide naturally produced by immune cells, epithelial cells, and barrier tissues. It plays a critical role in innate immunity by directly killing bacteria, viruses, and fungi, while also modulating inflammatory responses. Increasingly studied for chronic infections, biofilm disruption, and immune regulation.
Thymosin Alpha-1 activates dendritic cells, enhances T-cell maturation, and modulates Th1/Th2 balance. Thymalin provides a broader spectrum of thymic peptides that support thymic function and T-cell diversity. Together, they address both the specific (TA1) and general (Thymalin) aspects of thymic immune regulation.
Disrupts microbial membranes through electrostatic interaction with negatively charged bacterial surfaces, creating pores that kill pathogens. Also modulates immune responses by recruiting immune cells, promoting wound healing, and disrupting bacterial biofilms. Acts as a bridge between innate and adaptive immunity.
- Comprehensive immune optimization
- Post-viral recovery protocols
- Chronic infection support
- Longevity and immune aging (immunosenescence)
- Pre-travel immune preparation
- Immune system support
- Chronic infection management
- Biofilm disruption (Lyme, SIBO)
- Wound healing
- Upper respiratory infection support
- Injection site reactions from both peptides
- Potential for immune overstimulation
- Autoimmune flare risk in predisposed individuals
- Cost — both peptides required
- Limited data on combination safety
- Injection site reactions (pain, redness)
- Potential autoimmune activation at high doses
- Limited human clinical data for therapeutic use
- Overexpression linked to psoriasis and rosacea in some contexts
Thymosin Alpha-1 is FDA-approved internationally (Zadaxin) but not in the US. Thymalin has no FDA status. The combination protocol is not FDA-reviewed. Both are available through compounding pharmacies. TA1 is on the 503A Category 1 bulks list.
Not FDA-approved as a therapeutic. LL-37 is an endogenous human peptide being studied in clinical trials for wound healing and infection. Some compounding pharmacies have offered it, but it has no formal FDA category for compounding. Research is ongoing for topical wound applications.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.